A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).

  • STATUS
    Not Recruiting
Updated on 25 September 2021

Summary

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).
 

Description

  • Diagnosis of other autoimmune rheumatic disease. (i.e. RA, FMS, SLE)
  • History of known or suspected complete ankyloses of the spine.
  • Hx of recurrent herpes zoster/simplex >1 episode.
  • Hx of malignancy other than basal/squamous cell or cervical carcinoma in situ.
  • Hx of no more than two (2) TNF bDMARDs (i.e. enbrel, humira)
  • History/Exposure to Tofacitinib (Xeljanz)
  • bDMARD other than TNF Inhibitors (i.e. rituxan, Orencia)
  • Received recent live/attenuated vaccines.

Details
Condition Ankylosing spondylitis, *Healthy Children Studies
Clinical Study IdentifierTX217853
Last Modified on25 September 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note